Estrogen-related Receptor Gamma (ERRγ; NR3B3)

These nuclear receptor assay systems utilize proprietary non-human mammalian cells engineered to provide high-level expression of a hybrid form of Human ERRγ (also known as NR3B3). Reporter Cells also incorporate a responsive luciferase reporter gene. Quantifying expressed luciferase activity at the assay endpoint provides a sensitive surrogate measure of changes in ERRγ activity in treated cells. As is true in vivo, these reporter cells express ERRγ in a constitutive state of high-level activity in the putative absence of bound ligand. Interestingly, the ligand binding domain of ERRγ may be occupied by a ligand that produces further elevation of the receptor’s constitutive activity (an agonist response). Alternatively, ERRγ may have ligand-binding interactions that results in the loss of constitutive active (an inverse-agonist response). Therefore, the principle application of this assay system is in the screening of test samples to quantify the agonist or inverse-agonist activities that they may exert against human ERRγ.

For more information on ERRγ, visit the Nuclear Receptor Resource.

Service Assays: Human

The primary application of INDIGO’s cell-based nuclear receptor assays are to quantitatively assess the bioactivity of a test compound as an agonist (activator) or antagonist (inhibition of an agonist response) of a given receptor. Service assays include a positive control reference compound and ‘vehicle’ control for every experiment. A formal study report and all data files are provided to the client upon completion of the study. To receive a quote for your proposed study, complete & submit the online “Request a Quote” form or contact an INDIGO Customer Service Representative to discuss your desired study parameters.